Danaher Corporation
Stock Watch
Stock Watch will tell you what changes at Danaher Corporation.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 161.90 $ to 242.10 $ · Last price: 232.20 $ (As of: October 30, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 10/31/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Diagnostics & Research
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Danaher Corporation DHR | 164.0 | 43.8 | 24.0 | 59.4 | 22.9 | 2.9 | 8.8 |
| Thermo Fisher Scientific Inc TMO | 256.1 | 38.6 | 23.4 | 41.2 | 17.9 | 3.9 | 25.8 |
| Natera Inc NTRA | 59.7 | – | -26.8 | 65.2 | -12.4 | 35.9 | 114.4 |
| Agilent Technologies Inc A | 49.5 | 33.7 | 25.1 | 53.7 | 23.7 | 6.7 | 22.9 |
| Waters Corporation WAT | 45.4 | 55.6 | 51.3 | 56.3 | 2.8 | 7.0 | 34.9 |
| IQVIA Holdings Inc IQV | 44.8 | 32.6 | 17.0 | 33.0 | 13.6 | 5.9 | 23.5 |
| IDEXX Laboratories Inc IDXX | 43.8 | 41.3 | 27.9 | 62.5 | 31.8 | 10.4 | -12.3 |
| Illumina Inc ILMN | 35.7 | 39.8 | 30.4 | 67.9 | 18.3 | -0.8 | 138.4 |
| Mettler-Toledo International Inc MTD | 33.8 | 38.6 | 27.4 | 60.3 | 23.3 | 4.0 | 21.6 |
| Median of companies shown | 45.4 | 39.2 | 25.1 | 59.4 | 18.3 | 5.9 | 23.5 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 16,882 | 2,987 | 2,554 | 3.65 | 3,522 | 23,003 | 45,295 |
| 2017 | 18,330 | 3,150 | 2,492 | 3.53 | 3,478 | 26,358 | 46,649 |
| 2018 | 17,049 | 3,070 | 2,651 | 3.73 | 4,022 | 28,214 | 47,833 |
| 2019 | 17,911 | 3,362 | 2,557 | 3.52 | 3,952 | 30,271 | 62,082 |
| 2020 | 22,284 | 4,312 | 3,646 | 5.07 | 6,208 | 39,766 | 76,161 |
| 2021 | 29,453 | 8,050 | 6,433 | 8.73 | 8,358 | 45,167 | 83,184 |
| 2022 | 26,643 | 7,536 | 7,209 | 9.78 | 8,519 | 50,082 | 84,350 |
| 2023 | 23,890 | 5,202 | 4,743 | 6.38 | 7,164 | 53,486 | 84,488 |
| 2024 | 23,875 | 5,184 | 3,899 | 5.29 | 6,688 | 49,543 | 77,542 |
| 2025 | 24,568 | 5,137 | 3,614 | 5.08 | 6,416 | 52,534 | 83,464 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.47 | 1.90 | 6,538 | 2.10 | 16.60 | 2,019 | 1,503 |
| 2025: Q1 | 1.32 | -8.90 | 5,741 | -0.90 | 16.60 | 1,299 | 1,054 |
| 2025: Q2 | 0.77 | -36.80 | 5,936 | 3.40 | 9.30 | 1,338 | 1,090 |
| 2025: Q3 | 1.27 | 13.40 | 6,053 | 4.40 | 15.00 | 1,662 | 1,370 |
| 2025: Q4 | 1.68 | 14.30 | 6,838 | 4.60 | 17.50 | 2,117 | 1,746 |
| 2026: Q1 | 1.45 | 9.30 | 5,951 | 3.70 | 17.30 | 1,322 | 1,085 |
| 2026: Q2 | 1.23 | 59.70 | 6,265 | 5.50 | 13.90 | 1,534 | 1,265 |
| 2026: Q3 | 1.75 | 37.80 | 6,554 | 8.30 | 18.80 | 1,886 | 1,631 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Dividends
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 8.59 | 8.58 – 8.62 | 26,261 | 10.2% | 24 |
| 12/31/2027 | 9.32 | 9.17 – 9.49 | 28,283 | 8.5% | 24 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Instead of guessing what the stock is worth, we turn the question around: what free cash flow growth has to happen for today’s market value to add up? The assumptions behind it can be moved.
Today’s market value implies roughly 12.6% growth in free cash flow per year over ten years (assumptions: discount rate 10.0%, terminal growth 2.5%).
| Free cash flow (last twelve months) | $5.73B |
|---|---|
| Market cap | $163.98B |
| Free cash flow in year ten | $18.74B |
| Terminal value as a share of market value | 60.2% |
For comparison: over the past five years free cash flow shrank by 0.6% per year.
It shows which assumption is built into today’s price, not whether that assumption will hold. Every assumption can be changed with the sliders; the figures move with them.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -2.7%
- More than 10% revenue growth is expected for the coming year 9.3%
- Share count grows by less than 3% a year -1.2%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 24.3%
- Gross margin at 40% or higher and without meaningful erosion 60.9%
- Goodwill from acquisitions does not grow faster than revenue 51.7%
- Net debt below twice EBITDA 2.0 x EBITDA
- Operating cash flow covers the profits of the last three years 8,012 m
- Return on capital at 15% or higher, or up versus two years ago 6.7%
- Insiders hold at least 10% or are net buyers 10.7%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
7/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 4.3%
- Exp. sales growth 3Y > 5% 7.3%
- EBIT growth 10Y > 5% 6.2%
- Exp. EBIT growth 3Y > 5% 35.4%
- Net debt < 4x EBIT 2.7x
- EBIT positive, 10Y straight 10
- Max. EBIT decline < 50% 36.2%
- Return on equity > 15% –
- ROCE > 15% 6.7%
- Expected return > 10% 39.8%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 28, 2026 | Bouda Christopher | VP, Chief Accounting Officer | Sell | 3,253 | 234.58 | 763,094 |
| Oct 28, 2026 | Bouda Christopher | VP, Chief Accounting Officer | Other | 3,253 | 70.74 | 230,117 |
| Oct 28, 2026 | Bouda Christopher | VP, Chief Accounting Officer | Sell | 4,345 | 234.54 | 1,019,063 |
| Oct 28, 2026 | Bouda Christopher | VP, Chief Accounting Officer | Other | 4,345 | 70.74 | 307,365 |
| Oct 28, 2026 | McGrew Matthew | Executive Vice President | Sell | 15,603 | 236.09 | 3,683,773 |
| Oct 28, 2026 | McGrew Matthew | Executive Vice President | Other | 15,603 | 76.47 | 1,193,161 |
| Oct 28, 2026 | McGrew Matthew | Executive Vice President | Sell | 14,151 | 235.35 | 3,330,470 |
| Oct 9, 2026 | Rales Mitchell P | Chairman of Exec. Committee | Other | 500,000 | 0.00 | – |
| Oct 9, 2026 | Rales Steven M | Chairman | Other | 500,000 | 0.00 | – |
| Aug 21, 2026 | Blair Rainer | President & CEO | Sell | 7,755 | 219.35 | 1,701,053 |
The company
About the Company
Danaher Corporation entwickelt, fertigt und vermarktet professionelle, medizinische, Forschungs- und Industrieprodukte und -dienste in den USA, China und international. Das Unternehmen ist in den Segmenten Biotechnology, Life Sciences und Diagnostics tätig.
- Employees
- 58,000
- Headquarters
- Washington, DC
- Address
- 2200 Pennsylvania Avenue N.W., 20037-1701 Washington, United States
- Phone
- 202 828 0850
- Website
- danaher.com
- IPO Date
- 01/05/1979
- ISIN
- US2358511028
- Stock Split
- 1128:1000 on 10/02/2023
- Stock Split
- 1319:1000 on 07/05/2016
- Stock Split
- 2:1 on 06/14/2010
Management
| Name | Title | Birth Year |
|---|---|---|
| Steven M. Rales | Co-Founder & Chairman | 1951 |
| Julie Sawyer Montgomery | President, CEO & Director | 1972 |
| Mitchell P. Rales | Co-Founder & Director | 1957 |
| Jose-Carlos Gutierrez-Ramos Ph.D. | Senior VP & Chief Science Officer | 1962 |
| Matthew R. McGrew | Executive Vice President | 1972 |
| Rainer M. Blair | Senior Advisor | 1964 |
| Christopher Paul Riley | Executive VP of Biotechnology Group & CEO of Cytiva | 1974 |
| Matthew E. Gugino C.F.A., CPA | Executive VP & CFO | 1983 |
| Christopher M. Bouda | VP & Chief Accounting Officer | – |
| Rachel Marie Vatnsdal Olson | Vice President of Investor Relations | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 10/20/2026 DANAHER CORP /DE/ (DHR): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
- 10/13/2026 DANAHER CORP /DE/ (DHR): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Other Events SEC ↗
- 08/03/2026 DANAHER CORP /DE/ (DHR): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure; Other Events; Financial Statements and Exhibits SEC ↗
- 07/20/2026 DANAHER CORP /DE/ (DHR): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.